Table 1.
Patient demographics and baseline characteristics.
| Characteristic | Total N = 31 |
|---|---|
| Sex, n (%) | |
| Male | 14 (45.2) |
| Female | 17 (54.8) |
| Race, n (%) | |
| White | 27 (87.1) |
| Black or African American | 2 (6.5) |
| Asian | 2 (6.5) |
| Median (range) age, years | 64.0 (28–79) |
| <65 years | 16 (51.6%) |
| ≥65 years | 15 (48.4%) |
| WHO PS, n (%) | |
| 0 | 9 (29.0) |
| 1 | 22 (71.0) |
| Prior chemotherapy, n (%) | 31 (100.0) |
| Platinum-based chemotherapya | 22 (72.9) |
| Non-platinum-based chemotherapy | 31 (100.0) |
| Primary tumour location (tumour type added where applicable), n (%) | |
| Colon/rectum (colorectal) | 5 (16.2) |
| Breast | 4 (12.9) |
| Otherb | 4 (12.9) |
| Ovary | 4 (12.9) |
| Lungc | 3 (9.7) |
| Pancreas | 3 (9.7) |
| Bile duct (cholangiocarcinoma) | 2 (6.5) |
| Eye (melanoma) | 1 (3.2) |
| Oesophagus (squamous cell carcinoma) | 1 (3.2) |
| Parotid gland (adenoid cystic carcinoma) | 1 (3.2) |
| Prostate | 1 (3.2) |
| Thymus (thymoma) | 1 (3.2) |
| Uterus (endometrial) | 1 (3.2) |
WHO PS World Health Organization performance status.
aTen patients received prior cisplatin.
bIncluded gastrointestinal stromal tumour, liposarcoma of inguinal region, squamous cell carcinoma, and unknown primary carcinoma.
cIncluded pleural mesothelioma, lung carcinoma, and non-small cell lung cancer.